{
  "report_rows": [
    {
      "kpi": "Organic Revenue Growth (Q2 2026)",
      "prediction": "BEAT",
      "answer": "pred ~3.5% vs cons 3.05%",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Adj. EPS Diluted (Q2 2026)",
      "prediction": "BEAT",
      "answer": "pred ~$5.85 vs cons $5.76",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Pharma Services Revenue (Q2 2026)",
      "prediction": "MISS",
      "answer": "pred ~$1.88B vs cons $1.91B",
      "confidence": "LOW"
    }
  ],
  "guide_rows": [
    {
      "kpi": "FY 2026 Revenue (FY 2026)",
      "prediction": "BETTER",
      "answer": "guide ~$47.8B-$48.5B vs cons $47.77B",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "FY 2026 Adj. EPS (FY 2026)",
      "prediction": "BETTER",
      "answer": "guide ~$25.00-$25.40 vs cons $24.85",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Q3 2026 Organic Growth Commentary (Q3 2026)",
      "prediction": "BETTER",
      "answer": "implied ~4-4.5% vs cons ~3.2%",
      "confidence": "LOW"
    }
  ],
  "day1_residual_pct": 3.0,
  "day1_confidence": "MEDIUM",
  "day5_residual_pct": 1.5,
  "day5_path": "STABILIZE",
  "day5_rationale": "STABILIZE - FY guide raise drives modest estimate revisions; large run-in limits follow-through",
  "day5_confidence": "MEDIUM"
}